HIV-1 RT-associated Rnase H function inhibitors: Recent advances in drug development

Current Medicinal Chemistry

Volumn 17, Issue 26, 2010, Pages 2837-2853

  Tramontano, E ^a   Di Santo, R ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diketo acids; HIV 1; Hy drazones; Natural compounds; Reverse transcriptase; Ribonuclease H; RNase H; RNase H inhibitor

Indexed keywords

4 CHLOROPHENYLHYDRAZONE; ANTIRETROVIRUS AGENT; AVARONE; AZIDONEVIRAPINE; DEXTRAN SULFATE; HEPARIN; ILLIMAQUINONE; MADURAHYDROXYLACTONE; MAPPICINE; NAPHTHALENESULFONIC ACID DERIVATIVE; NAPHTHAZARIN; NAPHTHOQUINONE; NITROFURAN 2 CARBOXYLIC ACID CARBAMOYLMETHYL ESTER DERIVATIVE; PENTOSAN POLYSULFATE; PLUMBAGIN; RIBONUCLEASE; RIBONUCLEASE INHIBITOR; SHIKONIN; THIOCARBAMIC ACID; THUJAPLICIN; TROPOLONE; UNCLASSIFIED DRUG;

ARTICLE; DNA STRAND; DNA SYNTHESIS; DRUG INHIBITION; DRUG STRUCTURE; ESCHERICHIA COLI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; NONHUMAN; PHARMACOPHORE; PROTEIN FOOTPRINTING; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CATALYTIC DOMAIN; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; HIV REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR STRUCTURE; RIBONUCLEASE H;

EID: 77955648999     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792065045     Document Type: Article

References (87)

1. Telesnitsky, A.; Goff, S.P. In Retroviruses, Coffin, J.M.; Hughes, H; Varmus, H.E. Eds. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1997, pp. 121-160.
2. Hughes, S.H.; Arnold, E.; Hostomsky, Z. In Ribonucleases H, Crouch, R.J; Toulmé, J.J. Eds. Les Editions Inserm: Paris, 1998; pp.195-224.
3. Nikolenko, G. N.; Palmer, S.; Maldarelli, M.; Mellors, J.W.; Coffin,. J.M.; Pathak, V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA, 2005, 102, 2093-2098.
4. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res., 2008,134, 171-185.
5. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
6. Tramontano, E. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini-Rev. Med. Chem., 2006, 6, 727-737.
7. Schultz, S.J.; Champoux, J.J. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res., 2008, 134, 86-103.
8. Kati, W. M.; Johnson, K.A.; Jerva, L.F.; Anderson, K.S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol.Chem., 1992, 267, 25988-25997.
9. De Stefano, J.J.; Buiser, R.G.; Mallaber, L.M.; Myers, T.W.; Bambara, R.A.; Fay, P.J. Polymerization and RNase H activities of the reverse transcriptases from avian myeloblastosis, human immunodeficiency, and Moloney murine leukemia viruses are functionally uncoupled. J. Biol. Chem., 1991, 266, 7423-7431.
10. De Stefano, J.J.; Buiser, R.G.; Mallaber, L.M.; Bambara, R.A.; Fay, P.J. Human immunodeficiency virus reverse transcriptase displays a partially processive 3' to 5' endonuclease activity. J. Biol. Chem., 1991, 266, 24295-24301.
11. De Stefano, J.J; Mallaber, L.M.; Fay, P.J.; Bambara, R.A. Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase. Nucleic Acids Res., 1993, 21, 4330-4338.
12. Wisniewski, M.; Balakrishnan, M.; Palaniappan, C.; Fay, P.J.; Bambara, R.A. The sequential mechanism of HIV reverse transcriptase RNase H. J. Biol. Chem., 2000, 275, 37664-37671.
13. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 1992, 256, 1783-1790.
14. Nowotny, M.; Gaidamakov, S.A.; Ghirlando, R.; Cerritelli, S.M.; Crouch, R.J.; Yang, W. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell, 2007, 28, 264-276.
15. Abbondanzieri, E.A.; Bokinsky, G.; Rausch, J.W.; Zhang, J.X.; Le Grice, S.F.; Zhuang, X. Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature, 2008, 453, 184-189.
16. Liu, S.; Abbondanzieri, E.A.; Rausch, J.W.; Le Grice, S.F.J.; Zhuang, X. Slide into action: dynamic shuttling og HIV reverse transcriptase on nucleic acid substrates. Science, 2008, 322, 92-109.
17. Klumpp, K.; Hang, J.Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong Kai, P.; Overton, H.; Parkes, K.E.; Cammack, N.; Martin, J.A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res., 2003, 31, 6852-6859.
18. Klumpp, K.; Mirzadegan, T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Drug, 2006, 12, 1909-1922.
19. Keck, J.L.; Goedken, E.R.; Marqusee, S. Activation/attenuation odel for RNase H. A one-metal mechanism with second-metal nhibition. J. Biol. Chem., 1998, 273, 34128-34133.
20. Katayanagi, K.; Okumura, M.; Morikawa, K. Crystal structure of scherichia coli RNase HI in complex with Mg2+ at 2.8 A resolution: roof for a single Mg(2+)-binding site. Proteins, 1993, 17, 37-347.
21. Mizrahi, V.; Usdin, M.; Harington, A.; Dudding, L. Site-directed utagenesis of the conserved Asp-443 and Asp-498 carboxyterminal residues of HIV-1 reverse transcriptase. Nucleic Acids es., 1990, 18, 5359-5363.
22. Mizrahi, V.; Brooksbank, R.; Nkabinde, N. Mutagenesis of the onserved aspartic acid 443, glutamic acid 478, asparagine 494, nd aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase. Expression and biochemical analysis. J. Biol. Chem., 1994, 269, 19245-19249.
23. Champoux, J.J.; Schultz, S.J. Ribonuclease H: properties, substrate specificity and roles in retroviral reverse transcription. FEBS J., 2009, 276, 1506-1516.
24. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol., 2009, 385, 693-713.
25. Sarafianos, S.G.; Das, K.; Tantillo, C.; Clark, A.D.; Ding, J.; Whitcomb, J.M.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J., 2001, 20, 1449-1461.
26. Smith, J.S.; Roth, M.J. Specificity of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H in removal of the minus-strand primer, tRNA(Lys3). J. Biol. Chem., 1992, 267, 15071-15079.
27. Hizi, A.; Herschhorn, A. Retroviral reverse transcriptases (other than those of HIV-1 and murine leukemia virus): a comparison of their molecular and biochemical properties. Virus Res., 2008, 134, 203-220.
28. Ren, J.; Bird, L.E.; Chamberlain, P.P.; Stewart-Jones, G.B.; Stuart, D.I.; Stammers, D.K. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 14410-14415.
29. Sevilya, Z.; Loya, S.; Hughes, S.H.; Hizi, A. The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is affected by the thumb subdomain of the small protein subunits. J. Mol. Biol., 2001, 311, 957-971.
30. Hizi, A.; Tal, R.; Hughes, S.H. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli. Virology, 1991, 180, 339-346.
31. Hizi, A.; Tal, R.; Shaharabany, M.; Loya, S. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem., 1991, 266, 6230-6239.
32. Bochner, R.; Duvshani, A.; Adir, N.; Hizi, A. Mutagenesis of Gln294 of the reverse transcriptase of human immunodeficiency virus type-2 and its effects on the ribonuclease H activity. FEBS Lett., 2008, 582, 2799-2805.
33. Sevilya, Z.; Loya, S.; Adir, N.; Hizi, A. The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit. Nucleic Acids Res., 2003, 31, 1481-1487.
34. Singh, K.; Marchand, B.; Kirby, K.A.; Michailidis, E.; Sarafianos, S.G. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses, 2010, 2, 606-638.
35. Moelling, K.; Schulze, T.; Diringer, H. Inhibition of human immunodeficiency virus type 1 RNase H by sulfated polyanions J. Virol., 1989, 63, 5489-5491.
36. Andréola, M.L.; De Soultrait, V.R.; Fournier, M.; Parissi, V.; Desjobert, C.; Litvak, S. HIV-1 integrase and RNase H activities as therapeutic targets. Expert Opin. Ther. Targets, 2002, 6, 433-446.
37. Shaw-Reid, C.A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D.B.; Carroll, S.S.; Embrey, M.; Wai, J.S.; Miller, M.D.; Cole, J.L.; Hazuda, D.J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]- 2,4-dioxobutanoic acid. J. Biol. Chem., 2003, 278, 2777-2780.
38. Loya, S.; Tal, R.; Kashman, Y.; Hizi, H. Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 1990, 34, 2009-2012.
39. Loya, S.; Hizi, A. The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses. J. Biol. Chem., 1993, 268, 9323-9328.
40. Loya, S.; Hizi, A. The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives. FEBS Lett., 1990, 269, 131-134.
41. Loya, S.; Rudi, A.; Tal, R.; Kashman, Y.; Loya, Y.; Hizi, A. 3,5,8- Trihydroxy-4-quinolone, a novel natural inhibitor of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. Arch. Biochem. Biophys., 1994, 309, 315-322.
42. Min, B.S.; Miyashiro, H.; Hattori, M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother. Res., 2002, 16, 57-62.
43. Min, B.S.; Nakamura, N.; Miyashiro, H.; Kim, Y.H.; Hattori, M. Inhibition of human immunodeficiency virus type 1 reverse transcriptase and ribonuclease H activities by constituents of Juglans mandshurica. Chem. Pharm. Bull., 2000, 28, 194-200.
44. Kharlamova, T.; Esposito, F.; Zinzula, L.; Floris, G.; Cheng, Y.-C.; Dutschman, E.G.; Tramontano, E. Inhibition of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives. Med. Chem., 2009, 5, 398-410.
45. Marchand, C.; Beutler, J.A.; Wamiru, A.; Budihas, S.; Möllmann, U.; Heinisch, L.; Mellors, J.W.; Le Grice, S.F.; Pommier, Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother., 2008, 52, 361-364.
46. Takada, K.; Bermingham, A.; O'Keefe, B.R.; Wamiru, A.; Beutler,J.A.; Le Grice, S.F.J.; Lloyd, J.; Gustafson, K.R.; McMahon J.B. An HIV RNase H inhibitory 1,3,4,5-tetragalloylapiitol from the african plant. Hylodendron gabunensis. J. Nat. Prod., 2007, 70, 1647-1649.
47. Bokesch, H.R.; Wamiru, A.; Le Grice, S.F.J.; Beutler, J.A.; McKee, T.C.; McMahon, J.B. HIV-1 Ribonuclease H inhibitory phenolic glycosides from Eugenia hyemalis. J. Nat. Prod., 2008, 71, 1634-1636.
48. Dat, N.T.; Bae, K.H.; Wamiru, A.; McMahon, J.B.; Le Grice, S.F.J.; Bona, M.; Beutler, J.A.; Kim, Y.H. A dimeric lactone from Ardisia japonica with inhibitory activity for HIV-1 and HIV-2 ribonuclease H. J. Nat. Prod., 2007, 70, 839-841.
49. Lee, J.S.; Hattori, M.; Kim, J. Inhibition of HIV-1 protease and RNase H of HIV-1 reverse transcriptase activities by long chain phenols from the sarcotestas of Ginkgo biloba. Planta Med., 2008, 74, 532-534.
50. Budihas, S.R.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M.K.; Parniak, M.A.; Crouch, R.J.; McMahon, J.B.; Beutler, J.A.; Le Grice, S.F. Selective inhibition of HIV-1 reverse transcriptaseassociated ribonuclease H activity by hydroxylated tropolones. Nucleic Acid Res., 2005, 33, 1249-1256.
51. Semenova, E.A.; Johnson, A.A.; Marchand, C.; Davis, D.A.; Yarchoan, R,.; Pommier, Y. Preferential inhibition of the magnesiumdependent strand transfer reaction of HIV-1 integrase by alphahydroxytropolones. Mol. Pharmacol., 2006, 69, 1454-1460.
52. Didierjean, J.; Isel, C.; Querré, F.; Mouscadet, J.F.; Aubertin, A.M.; Valnot, J.Y.; Piettre, S.R.; Marquet, R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother., 2005, 49, 4884-4894.
53. Himmel,D.M.; Maegley,K.A.; Pauly,T.A.; Bauman,J.D.; Das,K.; Dharia,C.; Clark,A.D.J.; Ryan,K.; Hickey,M.J.; Love,R.A.; Hughes,S.H.; Bergqvist,S; Arnold,E. Structure of HIV-1 reverse transcriptase with the inhibitor β-thujaplicinol bound at the RNase H active site. Structure, 2009, 17, 1625-1635.
54. Curran, D.P.; Parniak, M.A.; Gabarda, A.; Zhang, W.; Luo, Z.; Chen, C.H.T. Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs. United States Patent Application Publication US2004/0077674 A1 2004.
55. Hnatyszyn, O.; Broussalis, A.; Herrera, G.; Muschietti, L.; Coussio, J.; Martino, V.; Ferraro, G.; Font, M.; Monge, A.; Martinez-Irujo, J.J.; Sanromàn, M.; Cuevas, M.T.; Santiago, E.; Lasarte, J.J. Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. Phytother. Res., 1999, 13, 206-209.
56. Min, B.S.; Kim, Y.H.; Tomiyama, M.; Nakamura, N.; Miyashiro, H.; Otake, T.; Hattori, M. Inhibitory effects of Korean plants on HIV-1 activities. Phyother. Res., 2001, 15, 481-486.
57. Tan, C.K.; Civil, R.; Mian, A.M.; So, A.G.; Downey, K.M. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry, 1991, 30, 4831-4835.
58. Zhan, X.; Tan, CK.; Scott, W.A.; Mian, A.M.; Downey, K.M.; So, A.G. Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide. Biochemistry, 1994, 33, 1366-1372.
59. Allen, S.J.W.; Krawczyk, S.H.; McGee, L.R.; Bischofberger, N.; Mulato, A.S.; Cherrington, J.M. Inhibition of HIV-1 RNase H activity by nucleotide dimers and monomers. Antivir. Chem. Chemother., 1996, 7, 37-45.
60. Matthes, E.; von Jant-Lipinski M. New dinucleotide derivatives are RNase H inhibitors - useful for the treatment of HIV and HBV infections. German Patent DE19640054A 1998.
61. Gao, W.Y.; Han, F.S.; Storm, C.; Egan, W.; Cheng, Y.C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol., 1992, 41, 223-229.
62. Andreola, M.L.; Pileur, F.; Calmels, C.; Ventura, M.; Tarrago-Litvak, L.; Toulmé, J.J.; Litvak, S. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry, 2001, 40, 10087-10094.
63. Hannoush, R.N.; Carriero, S.; Min, K.L.; Damha, M.J. Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem, 2004, 5, 527-533.
64. Borkow, G.; Fletcher, R.S.; Barnard, J.; Arion, D.; Motakis, D.; Dmitrienko, G.I.; Parniak, M.A. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by n-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry, 1997, 36, 3179-3185.
65. Arion, D.; Sluis-Cremer, N.; Min, K.-L.; Abram, M.E.; Fletcher, R.S.; Parniak. M.A. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. J. Biol. Chem., 2002, 277, 1370-1374.
66. Sluis-Cremer, N.; Arion, D.; Parniak, M.A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol., 2002, 62, 398-405.
67. Himmel, D.M.; Sarafianos, S.G.; Dharmasena, S.; Hossain, M.M.; McCoy-Simandle, K.; Ilina, T.; Clark, A.D., Jr.; Knight, J.L.; Julias, J.G.; Clark, P.K.; Krogh-Jespersen, K.; Levy, R.M.; Hughes, S.H.; Parniak, M.A.; Arnold, E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol., 2006, 1, 702-712.
68. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol., 2009, 385, 693-713.
69. Gabbara, S.; Davis, W.R.; Hupe, L.; Hupe, D.; Peliska J.A. Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry, 1999, 38, 13070-13076.
70. Davis, W.R.; Tomsho, J.; Nikam, S.; Cook, E.M.; Somand, D.; Peliska J.A. Inhibition of HIV-1 reverse transcriptase-catalyzed DNA strand transfer reactions by 4-chlorophenylhydrazone of mesoxalic acid. Biochemistry, 2000, 39, 14279-14291.
71. Mohan, P.; Loya, S.; Avidan, O.; Verma, S.; Dhindsa, G.S.; Wong, M.F.; Huang, P.P.; Yashiro, M.; Baba, M.; Hizi, A. Synthesis of naphthalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. J. Med. Chem., 1994, 37, 2513-2519.
72. Skillman, A.G.; Maurer, K.W.; Roe, D.C.; Stauber, M.J.; Eargle, D.; Ewing, T.J.; Muscate, A.; Davioud-Charvet, E.; Medaglia, M.V.; Fisher, R.J.; Arnold, E.; Gao, HQ.; Buckeit, R.; Boyer, P.L.; Hughes, S.H.; Kuntz, I.D.; Kenyon, G.L. A novel mechanism for inhibition of HIV-1 reverse transcriptase. Bioorg. Chem., 2002, 30, 443-458.
73. Parkes, K.E.; Ermet, P.; Fassler, J.; Ives, J.; Martin, J.A.; Merrett, J.H.; Obrecht, D.; Williams, G.; Klumpp, K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem., 2003, 46, 1153-1164.
74. Tomassini, J.; Selnick, H.; Davies, M.E.; Armstrong, M.E.; Baldwin, J.; Bourgeois, M.; Hastings, J.; Hazuda, D.; Lewis J.; McClements W. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds. Antimicrob. Agents Chemother., 1994, 38, 2827-2837.
75. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, JA.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287, 646-650.
76. Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V.G.; De Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem., 2004, 47, 14-17.
77. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov., 2005, 4, 236-248.
78. Evering, T. H.; Markowitz, M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today, 2007, 43, 865-877.
79. Shaw-Reid, C.A.; Feuston, B.; Munshi, V.; Getty, K.; Krueger, J.; Hazuda, D.J.; Parniak, M.A.; Miller, M.D.; Lewis, D. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry, 2005, 44, 1595-1606.
80. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2, 4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral. Res., 2005, 65, 117-124.
81. Hang, J.Q.; Rajendran, S.; Yang, Y.; Li, Y.; Wong Kai In, P.; Overton, H.; Parkes, K.E.; Cammack, N.; Martin, J.A., Klumpp, K. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem. Biophys. Res. Comm., 2004, 317, 321-329.
82. Billamboz, M.; Bailly, F.; Barreca, M.L.; De Luca, L.; Mouscadet, J.F.; Calmels, C.; Andréola, M.L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem., 2008, 51, 7717-7730.
83. Kirschberg, T.A.; Balakrishnan, M.; Squires, N.H.; Barnes, T.; Brendza, K.M.; Chen, X.; Eisenberg, E.J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J.K.; Wang, M.; Watkins, W.J.; Lansdon, E.B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J. Med. Chem., 2009, 52, 5781-5784.
84. Summa, V.; Petrocchi, A.; Matassa, V.G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Gonzales Paz, O.; Laufer, R.; Monteagudo, E.; Pace, P. 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIVintegrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem., 2006, 49, 6646-6649.
85. Fuji, H.; Urano, E.; Futahashi, Y.; Hamatake, M.; Tatsumi, J.; Hoshino, T.; Morikawa, Y.; Yamamoto, N.; Komano J. Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. J. Med. Chem., 2009, 52, 1380-1387.
86. Wendeler, M.; Lee, H.F.; Bermingham, A.; Miller, J.T.; Chertov, O.; Bona, M.K.; Baichoo, N.S.; Ehteshami, M.; Beutler, J.; O'Keefe, B.R.; Götte, M.; Kvaratskhelia, M.; Le Grice S. Vinylogous ureas as a novel class of inhibitors of reverse transcriptaseassociated ribonuclease H activity. ACS Chem. Biol., 2008, 3, 635-644.
87. Di Grandi, M.; Olson, M.; Prashad,A.S.; Bebernitz, G.; Luckay, A.; Mullen, S., Hu,Y.; Krishnamurthy,G.; Pitts,K.; O'Connell, J. Small molecule inhibitors of HIV RT ribonuclease H. Bioorg. Med. Chem. Lett., 2010, 20, 398-402.